Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Anti-vascular endothelial growth factor: the future treatment of choroidal neovascularization in pathologic myopia?

Zhu H, Wang FH, Sun XD.

Chin Med J (Engl). 2013;126(8):1578-83. Review. No abstract available.

2.

Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia.

Battaglia Parodi M, Iacono P, Bandello F.

Dev Ophthalmol. 2010;46:73-83. doi: 10.1159/000320010. Review.

PMID:
20703033
3.

Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia.

Tewari A, Dhalla MS, Apte RS.

Retina. 2006 Nov-Dec;26(9):1093-4. No abstract available.

PMID:
17151505
4.

Choroidal neovascularization in pathologic myopia.

Dave V, Narayanan R.

Am J Ophthalmol. 2010 Nov;150(5):752; author reply 752-3. doi: 10.1016/j.ajo.2010.07.005. No abstract available.

PMID:
21036211
5.

Avastin in myopic choroidal neovascularisation: is age the limit?

Wong D, Li KK.

Br J Ophthalmol. 2008 Aug;92(8):1011-2. doi: 10.1136/bjo.2007.135681. No abstract available.

PMID:
18653589
6.

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.

Laud K, Spaide RF, Freund KB, Slakter J, Klancnik JM Jr.

Retina. 2006 Oct;26(8):960-3. No abstract available.

PMID:
17031300
7.

Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia.

Cohen SY.

Retina. 2009 Sep;29(8):1062-6. doi: 10.1097/IAE.0b013e3181b1bb1a. Review.

PMID:
19734760
8.

Myopic choroidal neovascularization.

Ruiz-Moreno JM, López-Gálvez MI, Donate J, Gomez-Ulla F, García-Arumí J, García-Layana A, Sellés I, Reche J, Montero JA, Pazos B, Zapata MA, Pastor JC.

Ophthalmology. 2011 Dec;118(12):2521-3. doi: 10.1016/j.ophtha.2011.07.029. No abstract available.

PMID:
22136676
9.

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.

Nguyen QD, Shah S, Tatlipinar S, Do DV, Anden EV, Campochiaro PA.

Br J Ophthalmol. 2005 Oct;89(10):1368-70. No abstract available. Erratum in: Br J Ophthalmol. 2006 Jan;90(1):125.

10.

Ranibizumab for choroidal neovascularization secondary to causes other than age-related macular degeneration: a phase I clinical trial.

Heier JS, Brown D, Ciulla T, Abraham P, Bankert JM, Chong S, Daniel PE Jr, Kim IK.

Ophthalmology. 2011 Jan;118(1):111-8. doi: 10.1016/j.ophtha.2010.04.016.

PMID:
20678799
11.

Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Rosenfeld PJ.

Br J Ophthalmol. 2007 Feb;91(2):128-30. No abstract available.

12.

Ranibizumab treatment for choroidal neovascularization from causes other than age-related macular degeneration and pathological myopia.

Carneiro AM, Silva RM, Veludo MJ, Barbosa A, Ruiz-Moreno JM, Falcão MS, Brandão EM, Falcão-Reis FM.

Ophthalmologica. 2011;225(2):81-8. doi: 10.1159/000317908.

PMID:
20881442
13.

Anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization: do we need more evidence?

Lai TY.

Retina. 2012 Sep;32(8):1443-5. doi: 10.1097/IAE.0b013e31826956e4. No abstract available.

PMID:
22922844
15.

Papulopustular eruption after intravitreal bevacizumab (Avastin).

Amselem L, Diaz-Llopis M, Garcia-Delpech S, Montero J, Palomares P, Cervera E.

Acta Ophthalmol. 2009 Feb;87(1):110-1. doi: 10.1111/j.1755-3768.2007.01154.x. No abstract available.

16.

Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.

Parodi MB, Iacono P, Papayannis A, Kontadakis S, Cascavilla ML, Zucchiatti I, Bandello F.

Retina. 2013 Mar;33(3):593-7. doi: 10.1097/IAE.0b013e31826b6731.

PMID:
23190919
17.

Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.

Wakabayashi T, Ikuno Y, Gomi F.

Retina. 2011 May;31(5):880-6. doi: 10.1097/IAE.0b013e3181f2a293.

PMID:
21242860
18.

Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.

Gharbiya M, Giustolisi R, Allievi F, Fantozzi N, Mazzeo L, Scavella V, Gabrieli CB.

Am J Ophthalmol. 2010 Mar;149(3):458-64.e1. doi: 10.1016/j.ajo.2009.10.010.

PMID:
20172072
19.

Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.

Hernández-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Solís-Vivanco A, Reyna-Castelán E, Abraham-Marín M, Martínez-Castellanos MA, Aiello LP.

Retina. 2007 Jul-Aug;27(6):707-12.

PMID:
17621179
20.

Choroidal neovascularization in pathologic myopia: recent developments in diagnosis and treatment.

Soubrane G.

Surv Ophthalmol. 2008 Mar-Apr;53(2):121-38. doi: 10.1016/j.survophthal.2007.12.004. Review.

PMID:
18348878

Supplemental Content

Support Center